225 related articles for article (PubMed ID: 7531601)
1. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice.
Coles RE; Boyle TJ; DiMaio JM; Berend KR; Via DF; Lyerly HK
Ann Surg Oncol; 1994 Sep; 1(5):405-10. PubMed ID: 7531601
[TBL] [Abstract][Full Text] [Related]
2. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
Baiocchi RA; Caligiuri MA
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV)-associated lymphoproliferations in severe combined immunodeficient mice transplanted with Hodgkin's disease lymph nodes: implications of EBV-positive bystander B lymphocytes rather than EBV-infected Reed-Sternberg cells.
Meggetto F; Muller C; Henry S; Selves J; Mariamé B; Brousset P; Saati TA; Delsol G
Blood; 1996 Mar; 87(6):2435-42. PubMed ID: 8630408
[TBL] [Abstract][Full Text] [Related]
5. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
6. The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice.
Clinchy B; Vitetta ES
J Immunol Methods; 1998 Sep; 218(1-2):141-53. PubMed ID: 9819131
[TBL] [Abstract][Full Text] [Related]
7. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice.
Garnier JL; Cooper NR; Cannon MJ
Am J Pathol; 1993 Feb; 142(2):353-8. PubMed ID: 7679547
[TBL] [Abstract][Full Text] [Related]
8. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.
Boyle TJ; Tamburini M; Berend KR; Kizilbash AM; Borowitz MJ; Lyerly HK
Surgery; 1992 Aug; 112(2):378-86. PubMed ID: 1322566
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclosporine on human B-cell lymphoma development in vivo.
Boyle TJ; Coles RE; Kizilbash AM; Lyerly HK
Surg Oncol; 1992 Feb; 1(1):79-86. PubMed ID: 1341239
[TBL] [Abstract][Full Text] [Related]
10. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans.
Purtilo DT; Falk K; Pirruccello SJ; Nakamine H; Kleveland K; Davis JR; Okano M; Taguchi Y; Sanger WG; Beisel KW
Int J Cancer; 1991 Feb; 47(4):510-7. PubMed ID: 1847355
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
Rowe M; Young LS; Crocker J; Stokes H; Henderson S; Rickinson AB
J Exp Med; 1991 Jan; 173(1):147-58. PubMed ID: 1845872
[TBL] [Abstract][Full Text] [Related]
12. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice.
Abedi MR; Linde A; Christensson B; Mackett M; Hammarström L; Smith CI
Int J Cancer; 1997 May; 71(4):624-9. PubMed ID: 9178818
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome.
Ohshima K; Suzumiya J; Sugihara M; Nagafuchi S; Ohga S; Kikuchi M
Pathol Int; 1998 Dec; 48(12):934-43. PubMed ID: 9952337
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.
Dierksheide JE; Baiocchi RA; Ferketich AK; Roychowdhury S; Pelletier RP; Eisenbeis CF; Caligiuri MA; VanBuskirk AM
Blood; 2005 Feb; 105(4):1558-65. PubMed ID: 15498860
[TBL] [Abstract][Full Text] [Related]
16. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.
Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW
Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
19. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Jagiello C; O'Reilly RJ
Transplantation; 1996 Feb; 61(3):492-7. PubMed ID: 8610366
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant Epstein-Barr virus infection is associated with elevated levels of CD19+ B lymphocytes.
Morrissey PE; Lorber KM; Marcarelli M; Bia MJ; Kliger AS; Lorber MI
Transplantation; 1995 Feb; 59(4):637-40. PubMed ID: 7533350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
